Your shopping cart is currently empty

Alarelin Acetate is a synthetic GnRH agonist which can directly inhibit proliferation and DNA synthesis of rat GSMC through GnRH receptors.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $53 | In Stock | In Stock | |
| 10 mg | $87 | In Stock | In Stock | |
| 25 mg | $117 | In Stock | In Stock | |
| 50 mg | $158 | In Stock | In Stock | |
| 100 mg | $189 | In Stock | In Stock | |
| 500 mg | $475 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $123 | In Stock | In Stock |
| Description | Alarelin Acetate is a synthetic GnRH agonist which can directly inhibit proliferation and DNA synthesis of rat GSMC through GnRH receptors. |
| In vitro | Cell viability significantly decreased when exposed to alarelin, as compared to its absence. The peak stimulatory effect on cell viability occurred at a concentration of 10^-5 M, with alarelin demonstrating dose-dependent activity[1]. |
| In vivo | Alarelin effectively suppresses gastric acid secretion in rats through direct interaction with parietal cells and by impairing vagal function [2]. Additionally, Alarelin significantly elevates the ratio of G1 phase while reducing the S phase ratio in rat gastric smooth muscle cells (GSMC) [1]. |
| Cell Research | The cells are trypsinized in a solution of 2.5 g/L trypsin and seeded in a 96-well plate. After the cells are grown for 24 h to approximately 800 g/L subconfluent state, 0.1 mL medium containing 2.5% calf serum and various concentrations (0.001, 0.1, 10 μM) of alarelin is added to each well, respectively, and incubated for 24 h in a CO2 incubator. Each concentration is tested in at least 12 wells. Briefly, 15 μL of MTT solution is added to each well and incubated for 4 h. Then, the medium and MTT are removed and 150 μL of DMSO is added to each well and shaken for 10 min to dissolve the crystal. The OD is determined at 490 nm using an ELISA reader[1]. |
| Synonyms | Alarelin |
| Molecular Weight | 1167.34 |
| Formula | C56H78N16O12 |
| Cas No. | 79561-22-1 |
| Smiles | CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1 |
| Relative Density. | 1.482 g/cm3 |
| Sequence | H-Pyr-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-NHEt |
| Sequence Short | XHWSYALRP |
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 58 mg/mL (49.69 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (1.71 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.